All In Biotech

Drug Trial Radar · NCT05030584

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause

A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 52 Weeks in Postmenopausal Women

Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 628 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

628

Actual

Start

Aug 27, 2021

Primary completion

Mar 29, 2023

Study completion Feb 12, 2024

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Sep 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat women who have hot flashes after they have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life. The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people. In this study, the researchers will learn how well elinzanetant works compared to a placebo in women who have been through the menopause and have hot flashes. A placebo is a treatment that looks like a medicine but does not have any medicine in it. To compare these study treatments, the participants will record information about their hot flashes in an electronic diary. The researchers will study the number of hot flashes the participants have and how severe they are. They will study the results from before treatment and after 12 weeks of treatment. The participants in this study will take two capsules of either elinzanetant or the placebo once a day. The participants will take the study treatments for 52 weeks. During the study, the participants will visit their study site approximately 11 times and perform 2 visits by phone. Each participant will be in the study for approximately 62 weeks. During the study, the participants will: * record information about their hot flashes in an electronic diary * answer questions about their symptoms The doctors will: * check the participants' health * take blood samples * ask the participants questions about what medicines they are taking and if they are having adverse events An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

Conditions

  • Vasomotor Symptoms Associated With Menopause
  • Hot Flashes

Interventions

  • Elinzanetant (BAY3427080)Drug

    120 mg elinzanetant orally once daily

  • PlaceboDrug

    Matching placebo orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD])Time frame: Baseline to Week 12

Locations

86 sites in 9 countries. Site status is shown where the registry gives one.

  • Mobile ObGyn, P.C. | Mobile, AL

    Mobile, Alabama

  • Mesa Obstetricians and Gynecologists | Research Department

    Mesa, Arizona

  • National Institute of Clinical Research - Garden Grove

    Garden Grove, California

  • Marvel Clinical Research | Huntington Beach, CA

    Huntington Beach, California

  • Empire Clinical Research | Pomona, CA

    Pomona, California

  • Coastal Connecticut Research | New London, CT

    New London, Connecticut

  • IntimMedicine | Washington, DC

    Washington D.C., District of Columbia

  • Boca Midwifery

    Boca Raton, Florida

  • Helix Biomedics LLC | Boynton Beach, FL

    Boynton Beach, Florida

  • UF Health Women's Specialists - Emerson

    Jacksonville, Florida

  • Suncoast Clinical Research - Palm Harbor

    Palm Harbor, Florida

  • Physician Care Clinical Research LLC | Sarasota, FL

    Sarasota, Florida

  • Suncoast Clinical Research - New Port Richey

    Trinity, Florida

  • Paramount Research Solutions | College Park Location

    College Park, Georgia

  • Investigators Research Group, LLC

    Brownsburg, Indiana

  • Southern Clinical Research Associates

    Metairie, Louisiana

  • Southern Clinical Research, LLC

    Zachary, Louisiana

  • Johns Hopkins Hospital - Gynecology and Obstetrics

    Baltimore, Maryland

  • Boeson Research | Great Falls, MT

    Great Falls, Montana

  • Boeson Research | Missoula, MT

    Missoula, Montana

  • Affiliated Clinical Research, Inc. | Las Vegas, NV

    Las Vegas, Nevada

  • AMR - Las Vegas

    Las Vegas, Nevada

  • Elite Clinical Network (ECN) | Las Vegas Clinical Trials, LLC

    North Las Vegas, Nevada

  • M3 Wake Research | Raleigh, NC

    Raleigh, North Carolina

  • ClinOhio Research Services, LLC. | Columbus, OH

    Columbus, Ohio

  • HWC Women's Research Center | Englewood, OH

    Englewood, Ohio

  • Clinical Research Philadelphia | Philadelphia, PA

    Philadelphia, Pennsylvania

  • Venus Gynecology, LLC | Myrtle Beach, SC

    Myrtle Beach, South Carolina

  • Advances in Health, INC. | Houston, TX

    Houston, Texas

  • UTHealth Womens Research Program | Memorial City

    Houston, Texas

  • Elligo Health Research | Medical Colleagues of Texas

    Hurst, Texas

  • Elligo Health Research | Protenium Clinical Research

    Katy, Texas

  • Maximos Ob/Gyn

    League City, Texas

  • Tidewater Clinical Research - Norfolk

    Norfolk, Virginia

  • Eastern Virginia Medical School | OB/GYN Clinical Research Center

    Norfolk, Virginia

  • Seattle Clinical Research Center

    Seattle, Washington

  • CHU Saint-Pierre/UMC Sint-Pieter

    Bruxelles - Brussel, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • CHU de Liege | CHR Citadel - Department of Gyneacology and Obstetrics

    Liège, Belgium

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.